These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26457375)

  • 61. Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis.
    Giordano N; Papakostas P; Pecetti G; Nuti R
    J Biol Regul Homeost Agents; 2011; 25(4):487-92. PubMed ID: 22217982
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current management strategies for systemic sclerosis.
    Nihtyanova SI; Ong VH; Denton CP
    Clin Exp Rheumatol; 2014; 32(2 Suppl 81):156-64. PubMed ID: 24742450
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systemic sclerosis.
    Denton CP; Khanna D
    Lancet; 2017 Oct; 390(10103):1685-1699. PubMed ID: 28413064
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Long-term treatments for systemic sclerosis: what are the perspectives?].
    Mouthon L; Agard C; Garcia De La Peña-Lefebvre P; Guillevin L
    Ann Med Interne (Paris); 2002 Jun; 153(4):265-75. PubMed ID: 12218893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Systemic sclerosis].
    Villiger PM
    Ther Umsch; 2008 May; 65(5):283-7. PubMed ID: 18622933
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Evidence-based therapy of systemic sclerosis].
    Genth E
    Z Rheumatol; 2001 Dec; 60(6):464-8. PubMed ID: 11826742
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.
    Sacchetti C; Bottini N
    Curr Rheumatol Rep; 2017 May; 19(5):28. PubMed ID: 28397126
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Emerging targets of disease-modifying therapy for systemic sclerosis.
    Volkmann ER; Varga J
    Nat Rev Rheumatol; 2019 Apr; 15(4):208-224. PubMed ID: 30796362
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systemic sclerosis: markers and targeted treatments.
    Cutolo M; Sulli A; Pizzorni C; Paolino S; Smith V
    Acta Reumatol Port; 2016; 41(1):18-25. PubMed ID: 27115104
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeted immunotherapies in systemic sclerosis.
    Avouac J; Allanore Y
    Clin Exp Rheumatol; 2014; 32(2 Suppl 81):165-72. PubMed ID: 24742451
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeted therapies for systemic sclerosis.
    Denton CP; Ong VH
    Nat Rev Rheumatol; 2013 Aug; 9(8):451-64. PubMed ID: 23567456
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel therapeutic strategies in scleroderma.
    Denton CP; Black CM
    Curr Rheumatol Rep; 1999 Oct; 1(1):22-7. PubMed ID: 11123010
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lipids and eicosanoids in fibrosis: emerging targets for therapy.
    Castelino FV
    Curr Opin Rheumatol; 2012 Nov; 24(6):649-55. PubMed ID: 22810365
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.
    Young A; Khanna D
    Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Connective tissue diseases: Immunosuppressive therapy in SSc: what is the target?
    Boin F; Wigley F
    Nat Rev Rheumatol; 2009 Jul; 5(7):357-8. PubMed ID: 19568247
    [No Abstract]   [Full Text] [Related]  

  • 79. Systemic sclerosis.
    Allanore Y; Simms R; Distler O; Trojanowska M; Pope J; Denton CP; Varga J
    Nat Rev Dis Primers; 2015 Apr; 1():15002. PubMed ID: 27189141
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Are we too lenient with immunosuppression in severe cases of Systemic Sclerosis?
    Siegert E; Riemekasten G
    Rheumatology (Oxford); 2016 Oct; 55(10):1914-6. PubMed ID: 27330162
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.